title: Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.
abstract: Bronchial-associated lymphoid tissue (BALT) lymphoma is an extranodal primary pulmonary lymphoma. The optimal therapy for this rare disease is still debated, and few heterogeneous data are available in literature. The aim of our study was to critically review data of patients with BALT lymphoma treated in first-line therapy with fludarabine and mitoxantrone-containing regimens (with or without rituximab) to investigate the effectiveness and the safety of this approach and patients' survival. An observational retrospective study was performed on homogenous clinical data from 17 patients with biopsy-proven diagnosis of BALT. All the patients were treated with fludarabine and mitoxantrone-containing regimen therapy. Radiological findings were also reviewed to assess the role of (18) fluoro-deoxyglucose positron emission tomography in the initial assessment and in the monitoring of this extranodal lymphoma. A high percentage of response was observed: 82.3% of patients achieved a complete response, 11.8% a partial response. Furthermore, a very remarkable progression-free survival (71%) and overall survival (100%) were estimated at 14 years. No relevant toxicities were registered. Our results support the use of fludarabine and mitoxantrone-containing regimens as first-line therapy in the treatment of BALT lymphoma even if further data are necessary to consolidate our findings. Positron emission tomography scanning may provide additional valuable information in the assessment of BALT lymphoma.
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Cinzia
authors.initials: C
authors.lastname: Pellegrini
authors.forename: Letizia
authors.initials: L
authors.lastname: Gandolfi
authors.forename: Beatrice
authors.initials: B
authors.lastname: Casadei
authors.forename: Enrico
authors.initials: E
authors.lastname: Derenzini
authors.forename: Alessandro
authors.initials: A
authors.lastname: Broccoli
authors.forename: Federica
authors.initials: F
authors.lastname: Quirini
authors.forename: Lisa
authors.initials: L
authors.lastname: Argnani
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
authors.forename: Monica
authors.initials: M
authors.lastname: Celli
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti
authors.forename: Venerino
authors.initials: V
authors.lastname: Poletti
authors.forename: Vittorio
authors.initials: V
authors.lastname: Stefoni
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D018572:Disease-Free Survival; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D011877:Radionuclide Imaging; D012189:Retrospective Studies; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D008942:Mitoxantrone; D014740:Vidarabine; C024352:fludarabine